273 related articles for article (PubMed ID: 27328849)
1. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.
Ulz P; Belic J; Graf R; Auer M; Lafer I; Fischereder K; Webersinke G; Pummer K; Augustin H; Pichler M; Hoefler G; Bauernhofer T; Geigl JB; Heitzer E; Speicher MR
Nat Commun; 2016 Jun; 7():12008. PubMed ID: 27328849
[TBL] [Abstract][Full Text] [Related]
2. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
[TBL] [Abstract][Full Text] [Related]
3. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
4. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
[TBL] [Abstract][Full Text] [Related]
5. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
6. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy.
Bastacky S; Cieply K; Sherer C; Dhir R; Epstein JI
Hum Pathol; 2004 Mar; 35(3):281-9. PubMed ID: 15017583
[TBL] [Abstract][Full Text] [Related]
7. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.
Robbins CM; Tembe WA; Baker A; Sinari S; Moses TY; Beckstrom-Sternberg S; Beckstrom-Sternberg J; Barrett M; Long J; Chinnaiyan A; Lowey J; Suh E; Pearson JV; Craig DW; Agus DB; Pienta KJ; Carpten JD
Genome Res; 2011 Jan; 21(1):47-55. PubMed ID: 21147910
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis of genomic aberrations associated with prostate cancer progression.
Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
[TBL] [Abstract][Full Text] [Related]
9. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
10. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
11. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
[TBL] [Abstract][Full Text] [Related]
12. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
13. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.
Liu W; Xie CC; Zhu Y; Li T; Sun J; Cheng Y; Ewing CM; Dalrymple S; Turner AR; Sun J; Isaacs JT; Chang BL; Zheng SL; Isaacs WB; Xu J
Neoplasia; 2008 Aug; 10(8):897-907. PubMed ID: 18670647
[TBL] [Abstract][Full Text] [Related]
14. Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.
Cho H; Herzka T; Stahlhut C; Watrud K; Robinson BD; Trotman LC
Methods; 2015 May; 77-78():197-204. PubMed ID: 25592467
[TBL] [Abstract][Full Text] [Related]
15. Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer.
Jaratlerdsiri W; Chan EKF; Gong T; Petersen DC; Kalsbeek AMF; Venter PA; Stricker PD; Bornman MSR; Hayes VM
Cancer Res; 2018 Dec; 78(24):6736-6746. PubMed ID: 30217929
[TBL] [Abstract][Full Text] [Related]
16. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
17. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
Lapointe J; Li C; Giacomini CP; Salari K; Huang S; Wang P; Ferrari M; Hernandez-Boussard T; Brooks JD; Pollack JR
Cancer Res; 2007 Sep; 67(18):8504-10. PubMed ID: 17875689
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
Sun C; Dobi A; Mohamed A; Li H; Thangapazham RL; Furusato B; Shaheduzzaman S; Tan SH; Vaidyanathan G; Whitman E; Hawksworth DJ; Chen Y; Nau M; Patel V; Vahey M; Gutkind JS; Sreenath T; Petrovics G; Sesterhenn IA; McLeod DG; Srivastava S
Oncogene; 2008 Sep; 27(40):5348-53. PubMed ID: 18542058
[TBL] [Abstract][Full Text] [Related]
20. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization.
El Gedaily A; Bubendorf L; Willi N; Fu W; Richter J; Moch H; Mihatsch MJ; Sauter G; Gasser TC
Prostate; 2001 Feb; 46(3):184-90. PubMed ID: 11170146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
